# Efficacy and Safety Study of IFX-1 in Patients With Moderate to Severe Hidradenitis Suppurativa (HS)

> **NCT03487276** · PHASE2 · COMPLETED · sponsor: **InflaRx GmbH** · enrollment: 179 (actual)

## Conditions studied

- Hidradenitis Suppurativa (HS)

## Interventions

- **DRUG:** IFX-1
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03487276
- **Lead sponsor:** InflaRx GmbH
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-02-26
- **Primary completion:** 2019-05-27
- **Final completion:** 2020-01-27
- **Target enrollment:** 179 (ACTUAL)
- **Last updated:** 2021-04-08

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03487276

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03487276, "Efficacy and Safety Study of IFX-1 in Patients With Moderate to Severe Hidradenitis Suppurativa (HS)". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03487276. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*